New combo therapy shows promise for tough liver cancer cases

This study tested a new treatment for people with advanced liver cancer that has spread into the major blood vessels of the liver. The treatment combines a special type of radiation (moderate-dose hypofractionated radiotherapy) with an immunotherapy drug called tislelizumab. The goal was to see if this combination could help patients live longer and control the cancer. The study included 30 patients and found that the approach was feasible, with some patients responding well, though maintenance therapy with another drug (lenvatinib) was often needed to keep the cancer in check.